Los Angeles Capital Management
RCUS icon

Los Angeles Capital Management’s Arcus Biosciences RCUS Stock Holding History

Los Angeles Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.5K Hold
347
– – ﹤0.01% 2010
2025
Q4 		$7.01K Buy
+347
New +$7.08K ﹤0.01% 2207
2021
Q3 		– Sell
-10,085
Closed -$277K – 1572
2021
Q2 		$277K Sell
10,085
-600
-6% -$17.1K ﹤0.01% 1417
2021
Q1 		$300K Buy
10,685
+2,960
+38% +$103K ﹤0.01% 1435
2020
Q4 		$201K Buy
+7,725
New +$187K ﹤0.01% 1471

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Los Angeles Capital Management's RCUS Position: Q1 2026 in Review

Los Angeles Capital Management held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 347 shares worth $7.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Los Angeles Capital Management first reported a position in RCUS in Q4 2020 and has held it in 5 quarters since. The position peaked at $300K in Q1 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Los Angeles Capital Management held 347 shares of Arcus Biosciences worth $7.5K as of Q1 2026.
  • Los Angeles Capital Management left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2010 holding.
  • Los Angeles Capital Management first reported a position in Arcus Biosciences in Q4 2020 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Arcus Biosciences position peaked at $300K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.